



September 2026

Dear Angelman Syndrome Community,

Ionis is pleased to inform you that we have posted the design of [CHAMPION](#) (NCT07782827), our Phase 3 clinical trial to evaluate the efficacy of ION582 (obudanersen) in people with Angelman syndrome (AS) due to paternal uniparental disomy (UPD), or imprinting center defects (abbreviated as either ID or ICD), on [clinicaltrials.gov](#).¹ Some additional aspects of the study include:

- CHAMPION is a single-arm, open-label clinical trial. Everyone will receive obudanersen (80mg) throughout the trial. There is no control or placebo arm being utilized in CHAMPION.¹
- CHAMPION consists of a 60-week Treatment Evaluation Period followed by a Long-Term Extension Period of about 25 months. Obudanersen (80 mg) will be administered via lumbar puncture every 12 weeks during both periods, for a total of 14 doses.¹
- Up to approximately 30 people will be enrolled in CHAMPION across two cohorts. Cohort 1 will include individuals with UPD/ID AS between the ages of 2 and 18, and Cohort 2 will include adults between the ages of 18 and 50. More individuals will be enrolled in Cohort 1 than in Cohort 2. Additional eligibility criteria apply.¹
- CHAMPION enrollment will be limited to clinical trial sites in the United States. Sites will be added to the [clinicaltrials.gov](#) page on a rolling basis as they are activated to initiate enrollment.¹

The design of CHAMPION was informed by input from clinicians, regulators, advocacy leaders, and caregivers of individuals with UPD/ID AS, as well as other similar meetings coordinated by Ionis.² Ionis thanks all those in the Angelman community who have informed and supported research efforts over the years.

Sincerely,

The Obudanersen Team

The following is additional information you may find helpful:

Where can someone interested in learning more about CHAMPION get additional information?

Individuals interested in learning more about participating in a clinical trial should speak with their doctor. Additional information about CHAMPION is available online at <https://clinicaltrials.gov/study/NCT07782827>.¹

Why will CHAMPION only enroll in the United States?

Ionis recognizes that there is high interest among the UPD/ID Angelman syndrome community to participate in clinical trials. The decision to limit enrollment in CHAMPION to sites in the US was made to support rapid and efficient enrollment and completion of the trial.

What is REVEAL, and how is it related to CHAMPION?

Ionis is seeking to understand the safety and efficacy of obidanersen in Angelman syndrome. REVEAL ([NCT06914609](#)) is a global, randomized, double-blind, controlled Phase 3 clinical trial of obidanersen in individuals with a clinical diagnosis of AS with genetic confirmation of either a *UBE3A* deletion or *UBE3A* mutation³ CHAMPION is also a Phase 3 clinical trial, but it is open-label and limited to individuals with UPD/ID Angelman syndrome.¹

The [Angelman Syndrome Foundation](#) and the [Foundation for Angelman Syndrome Therapeutics \(FAST\)](#) are community organizations that provide resources and support to patients, caregivers, and others impacted by Angelman syndrome. For more information about Ionis, visit www.ionis.com or email padvocacy@ionis.com.

Abbreviations: AS, Angelman syndrome; UPD, paternal uniparental disomy; ID or ICD, imprinting center defects

References: 1. Clinicaltrials.gov NCT07782827 CHAMPION, 2. UPD/ID Caregiver Advisory Meeting 2026, 3. Clinicaltrials.gov NCT06914609 REVEAL

PA-US-AS-260004 v1 09/2026